Vivos Therapeutics, Inc. (VVOS): Capital Expenditures
$2.34M
Year ended 2025-12-31
$1.88M
Trailing 12 months to 2026-06-30
+36.3%
3-year compound annual growth
+81.2%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $2.34M | +312.1% | 2026-04-15, From 2025-01-01 |
| 2024-12-31 | $568.0K | -29.3% | 2026-04-15, From 2024-01-01 |
| 2023-12-31 | $803.0K | -13.1% | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | $924.0K | -61.4% | 2024-07-30, From 2022-01-01 |
| 2021-12-31 | $2.40M | n/m | 2023-03-30, From 2021-01-01 |
| 2020-12-31 | $120.0K | -31.7% | 2022-03-31, From 2020-01-01 |
| 2019-12-31 | $175.6K | n/a | 2021-03-25, From 2019-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Vivos Therapeutics, Inc. (VVOS) | 2025-12-31 | $2.34M | +312.1% |
| Nephros Inc (NEPH) | 2024-12-31 | $55.0K | -26.7% |
| Profound Medical Corp. (PROF) | 2025-12-31 | $176.0K | n/a |
| Sonoma Pharmaceuticals, Inc. (SNOA) | 2026-03-31 | $192.0K | +140.0% |
| Allurion Technologies, Inc. (ALUR) | 2024-12-31 | $611.0K | -62.0% |
| DarioHealth Corp. (DRIO) | 2025-12-31 | $142.0K | +2.9% |
| Baird Medical Investment Holdings Ltd (BDMD) | 2025-12-31 | $42.3K | -98.5% |
| Nexgel, Inc. (NXGL) | 2025-12-31 | $68.0K | -84.7% |
| Sensus Healthcare, Inc. (SRTS) | 2025-12-31 | $196.0K | -29.0% |
Compare VVOS, NEPH, PROF, SNOA side by side · Screen every company in Surgical & Medical Instruments & Apparatus ↗